Tudor Investment Corp ET AL Reduces Stake in Pediatrix Medical Group

Hedge fund decreases ownership in pediatric healthcare provider

Mar. 28, 2026 at 11:14am

Tudor Investment Corp ET AL, a major institutional investor, has reduced its stake in Pediatrix Medical Group, Inc. (NYSE: MD) by nearly 49% during the third quarter, according to a recent SEC filing. The hedge fund now owns approximately 143,560 shares of the pediatric healthcare provider, down from over 281,000 shares previously.

Why it matters

This reduction in ownership by a prominent investment firm could signal broader market sentiment or concerns about Pediatrix's performance. As a major player in the pediatric subspecialty care space, changes to Pediatrix's shareholder base are noteworthy and may impact the company's strategic direction.

The details

According to the SEC filing, Tudor Investment Corp ET AL sold 137,553 shares of Pediatrix Medical Group during the third quarter. The hedge fund now owns around 0.17% of the company's outstanding stock, down from 0.33% previously. No specific reasons were provided for the sell-off, though portfolio adjustments and changing investment theses are common factors behind institutional ownership changes.

  • Tudor Investment Corp ET AL filed the 13F disclosure with the SEC on March 28, 2026, reporting its Q3 2025 holdings.

The players

Tudor Investment Corp ET AL

A prominent hedge fund that has reduced its stake in Pediatrix Medical Group.

Pediatrix Medical Group, Inc.

A national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care.

Got photos? Submit your photos here. ›

The takeaway

This reduction in ownership by Tudor Investment Corp ET AL could signal broader market concerns about Pediatrix Medical Group's performance or future prospects, though the specific reasons behind the sell-off remain unclear. As a major player in the pediatric healthcare space, changes to Pediatrix's shareholder base are worth monitoring for potential impacts on the company's strategic direction.